Search
QR-333
go.drugbank.com/drugs/DB05533Investigationalthat can lead to numbness, skin ulcers, constant pain or extreme sensitivity to a stimulus. … QR-333 is a concentrated and standardized nutrient based active compounds dosed in a topical cream designed to reduce oxidative stress and treat symptoms of Diabetic Peripheral Neuropathy, a nerve disorder
NKG2D-ACE2 CAR-NK Cell
go.drugbank.com/drugs/DB15727InvestigationalFirst used with autologous human T cells (CAR-T) as cancer immunotherapies, these receptors are now being engineered onto natural killer (NK) cells due to lower potential for graft-versus-host disease … The ACE2 is a receptor for SARS-Cov-2, binding to the S-protein of the viral envelope and competitively inhibiting SARS-Cov-2 infection of type II alveolar epithelial cells.
Sorbitol
go.drugbank.com/drugs/DB01638ApprovedInvestigationalA polyhydric alcohol with about half the sweetness of sucrose. Sorbitol occurs naturally and is also produced synthetically from glucose. It was formerly used as a diuretic and may still be used as a laxative and in irrigating solutions ...
Ulimorelin
go.drugbank.com/drugs/DB12128InvestigationalUlimorelin is a novel small molecule ghrelin agonist being developed by Tranzyme Pharma as a first-in-class treatment for both POI and diabetic gastroparesis, serious medical conditions in which motility
Ibritumomab tiuxetan
go.drugbank.com/drugs/DB00078ApprovedIbritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light chains of 213 amino acids each.
ABT-510
go.drugbank.com/drugs/DB05434InvestigationalIt is developed by Abbott Laboratories for the treatment of Solid Tumors, Lymphoma and Melanoma.
RI 624
go.drugbank.com/drugs/DB05892ExperimentalRI 624 is being developed by Rinat and is currently in Phase I clinical trials.
Gantacurium
go.drugbank.com/drugs/DB05710InvestigationalIt is being developed by Avera Pharmaceuticals.
DLO6002
go.drugbank.com/drugs/DB05179ExperimentalDLO6002 is developed by Summit Corporation and is in phase I of clinical trials for the treatment of Parkinson's disease.
Orbifloxacin
go.drugbank.com/drugs/DB11443ExperimentalVet approvedIt is marketed by Schering-Plough Animal Health and approved for certain infections in dogs.